- Thomas J. Appio appointed interim CEO of Bausch + Lomb, effective Oct. 12, 2026
- Appio remains CEO of Bausch Health and chairman of Bausch + Lomb board
- Brent Saunders departed by mutual agreement with the board
- Preliminary Q3 results support expected raise of full-year 2026 adjusted EBITDA guidance
- Full guidance update to be provided with Q3 earnings on Oct. 28
- Bausch + Lomb appointed Thomas J. Appio as interim CEO, replacing Brent Saunders by mutual agreement. Appio will continue as CEO of parent Bausch Health. The companies also announced they expect to raise full-year 2026 adjusted EBITDA guidance based on preliminary Q3 strength.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card